- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Therapy, Midomafetamine, Placebo
- Behavioral · Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Boulder, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer, Adjustment Disorders
- Interventions
- MDMA
- Drug
- Lead sponsor
- Sunstone Medical
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- 3,4 Methylenedioxymethamphetamine, Prolonged Exposure
- Drug · Behavioral
- Lead sponsor
- Healing Breakthrough
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- PTSD
- Interventions
- MDMA, Group Therapy
- Drug · Behavioral
- Lead sponsor
- Portland VA Research Foundation, Inc
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Vancouver, Washington
- Conditions
- PTSD
- Interventions
- Midomafetamine HCl
- Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Boulder, Colorado + 6 more
- Conditions
- Startle Response
- Interventions
- Placebo, Midomafetamine, Acoustic startle
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Psychological Effects of Study Drug
- Interventions
- Lactose (inactive placebo), midomafetamine HCl
- Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2022
- U.S. locations
- 3
- States / cities
- Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina
- Conditions
- Social Anxiety Disorder
- Interventions
- MDMA, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Jason B Luoma
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Psilocybin, MDMA
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anxiety Disorder, Cancer
- Interventions
- Stage 1 Active Methylenedioxymethamphetamine, Stage 1 Low dose Methylenedioxymethamphetamine, Psychotherapy, Stage 2 Active Methylenedioxymethamphetamine
- Drug · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Autism Spectrum Disorder, ASD
- Interventions
- DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
- Drug
- Lead sponsor
- Definium Therapeutics US, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Midomafetamine, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 2
- States / cities
- Rockville, Maryland • Waynesville, North Carolina
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Midomafetamine HCl, Lactose placebo pill, Therapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Mt. Pleasant, South Carolina
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- 3,4-Methylenedioxymethamphetamine (MDMA), Placebo, Massed Prolonged Exposure (PE)
- Drug · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Social Anxiety in Autistic Adults
- Interventions
- Placebo, Midomafetamine HCl, Therapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- MDMA Discontinuation Syndrome
- Interventions
- 3,4-methylenedioxymethamphetamine or Placebo
- Drug
- Lead sponsor
- California Pacific Medical Center Research Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- 3,4-methylenedioxymethamphetamine, d-amphetamine, Therapy
- Drug · Behavioral
- Lead sponsor
- Stephen Robert Marder
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Healthy, MDMA ('Ecstasy')
- Interventions
- 3,4-Methylenedioxymethamphetamine, methamphetamine
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Psychedelic Effects in Healthy Volunteers
- Interventions
- Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Low dose MDMA-assisted therapy, Medium dose MDMA-assisted therapy, Full dose MDMA-assisted therapy, Therapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Mt. Pleasant, South Carolina
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Therapy, midomafetamine HCl, Placebo
- Behavioral · Drug
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 11
- States / cities
- North Hollywood, California • San Francisco, California • Boulder, Colorado + 6 more
- Conditions
- PTSD
- Interventions
- MDMA
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- PTSD
- Interventions
- Midomafetamine, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- Resilient Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- The Bronx, New York